标题
Advancing Strategies for Proteolysis-Targeting Chimera Design
作者
关键词
-
出版物
Journal of Medicinal Chemistry
Volume 66, Issue 4, Pages 2308-2329
出版商
American Chemical Society (ACS)
发表日期
2023-02-15
DOI
10.1021/acs.jmedchem.2c01555
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
- (2022) Yuqian Yan et al. CHEMICAL COMMUNICATIONS
- Importance of Three-Body Problems and Protein–Protein Interactions in Proteolysis-Targeting Chimera Modeling: Insights from Molecular Dynamics Simulations
- (2022) Wenqing Li et al. Journal of Chemical Information and Modeling
- Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure–Activity Relationship Studies
- (2022) Xufen Yu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders
- (2022) Jibu Lu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications
- (2022) Nathaniel J. Henning et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions
- (2022) Le Guo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Designing Soluble PROTACs: Strategies and Preliminary Guidelines
- (2022) Diego García Jiménez et al. JOURNAL OF MEDICINAL CHEMISTRY
- In Silico Modeling and Scoring of PROTAC-Mediated Ternary Complex Poses
- (2022) Junzhuo Liao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clinical considerations for the design of PROTACs in cancer
- (2022) Cristina Nieto-Jiménez et al. Molecular Cancer
- HJM-561, a potent, selective and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations
- (2022) Yong Du et al. MOLECULAR CANCER THERAPEUTICS
- Targeted protein degraders: a call for collective action to advance safety assessment
- (2022) Lyn H. Jones et al. NATURE REVIEWS DRUG DISCOVERY
- Deubiquitinating enzymes: Promising targets for drug resistance
- (2022) Fujing Ge et al. DRUG DISCOVERY TODAY
- Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras
- (2022) Xufen Yu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma
- (2022) Jingyu Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Feasible Column Chromatography-Free, Multi-Gram Scale Synthetic Process of VH032 Amine, Which Could Enable Rapid PROTAC Library Construction
- (2022) Wei Yan et al. ACS Omega
- Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2
- (2022) Xingui Liu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- PROTAC-DB 2.0: an updated database of PROTACs
- (2022) Gaoqi Weng et al. NUCLEIC ACIDS RESEARCH
- Molecular glue CELMoD compounds are regulators of cereblon conformation
- (2022) Edmond R. Watson et al. SCIENCE
- The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
- (2022) Alison M. Kurimchak et al. Science Signaling
- A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
- (2022) Christiane Kofink et al. Nature Communications
- A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs
- (2022) Irene Preet Bhela et al. Journal of Medicinal Chemistry
- Discovery of Orally Bioavailable N-Benzylpiperidinol Derivatives as Potent and Selective USP7 Inhibitors with In Vivo Antitumor Immunity Activity against Colon Cancer
- (2022) Xing Li et al. Journal of Medicinal Chemistry
- Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer
- (2021) Hidetomo Yokoo et al. ACS Medicinal Chemistry Letters
- Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins
- (2021) Ryosuke Shirasaki et al. Cell Reports
- Discovery of Thalidomide-based PROTAC Small Molecules as the Highly Efficient SHP2 Degraders
- (2021) Xiangbo Yang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Discovery of SIAIS001 as an Oral Bioavailability ALK Degrader Constructed from Alectinib
- (2021) Chaowei Ren et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems
- (2021) Xiaojuan Qu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta
- (2021) Nan Bai et al. Journal of Chemical Information and Modeling
- Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
- (2021) Peter S. Dragovich et al. JOURNAL OF MEDICINAL CHEMISTRY
- PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery
- (2021) Giuseppe Ermondi et al. MOLECULES
- Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2
- (2021) Guangyan Du et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
- (2021) Linrong Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and resistance mechanism of a selective CDK12 degrader
- (2021) Baishan Jiang et al. Nature Chemical Biology
- Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
- (2021) Robert P. Law et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Challenges and opportunities for in vivo PROTAC delivery
- (2021) Andrew B Benowitz et al. Future Medicinal Chemistry
- Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
- (2021) Weiguo Xiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP
- (2021) Mengzhu Zheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
- (2021) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile
- (2021) Chaowei Ren et al. JOURNAL OF MEDICINAL CHEMISTRY
- Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
- (2021) Troy A. Bemis et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
- (2021) Jaeki Min et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
- (2021) Svenja Lier et al. BIOORGANIC CHEMISTRY
- Integrative Modeling of PROTAC-Mediated Ternary Complexes
- (2021) Gaoqi Weng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design
- (2021) Hidetomo Yokoo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity
- (2021) Victoria G. Klein et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemoselective Electrosynthesis Using Rapid Alternating Polarity
- (2021) Yu Kawamata et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The PROTAC gold rush
- (2021) Ken Garber NATURE BIOTECHNOLOGY
- USP15 antagonizes CRL4CRBN-mediated ubiquitylation of glutamine synthetase and neosubstrates
- (2021) Thang Van Nguyen PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
- (2021) Xufen Yu et al. Science Translational Medicine
- Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
- (2021) Dongwen Lv et al. Nature Communications
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- Flexibility in early drug discovery: focus on the beyond-Rule-of-5 chemical space
- (2020) Giulia Caron et al. DRUG DISCOVERY TODAY
- Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
- (2020) Ning Sun et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Fundamental aspects of DMPK optimization of targeted protein degraders
- (2020) Carina Cantrill et al. DRUG DISCOVERY TODAY
- N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure–activity relationships and X-ray crystallographic studies
- (2020) Minglei Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Selective Small Molecule Degraders of BRAF-V600E
- (2020) Xiao-Ran Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase
- (2020) Mei-Xin Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Macromolecular modeling and design in Rosetta: recent methods and frameworks
- (2020) Julia Koehler Leman et al. NATURE METHODS
- PROTAC Technology: Opportunities and Challenges
- (2020) Hongying Gao et al. ACS Medicinal Chemistry Letters
- Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
- (2020) Yonghan He et al. Nature Communications
- A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
- (2020) Bingqi Tong et al. ACS Chemical Biology
- Structural Insights into PROTAC-Mediated Degradation of Bcl-xL
- (2020) Chun-wa Chung et al. ACS Chemical Biology
- Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective
- (2020) Andy Pike et al. DRUG DISCOVERY TODAY
- Degraders early developability assessment: face-to-face with molecular properties
- (2020) Giuseppe Ermondi et al. DRUG DISCOVERY TODAY
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation
- (2020) Craig Donoghue et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo
- (2020) Mingming Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes
- (2020) Daniel Zaidman et al. Journal of Chemical Information and Modeling
- Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation via New In Silico Methodologies
- (2020) Michael L. Drummond et al. Journal of Chemical Information and Modeling
- Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
- (2020) Wen-Hao Guo et al. Nature Communications
- Bardoxolone conjugation enables targeted protein degradation of BRD4
- (2020) Bingqi Tong et al. Scientific Reports
- Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
- (2020) Katherine A. Donovan et al. CELL
- Discovery of potent small molecule PROTACs targeting mutant EGFR
- (2020) Hong-Yi Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
- (2020) Shenxin Zeng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes
- (2020) James Schiemer et al. Nature Chemical Biology
- Solution Conformations Shed Light on PROTAC Cell Permeability
- (2020) Yoseph Atilaw et al. ACS Medicinal Chemistry Letters
- Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo
- (2020) Guoshun Luo et al. Acta Pharmaceutica Sinica B
- A novel cereblon modulator for targeted protein degradation
- (2019) Sung Ah Kim et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
- (2019) Jiantao Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
- (2019) Blake E. Smith et al. Nature Communications
- ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
- (2019) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
- (2019) Michael L. Drummond et al. Journal of Chemical Information and Modeling
- Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications
- (2019) Carl C. Ward et al. ACS Chemical Biology
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction
- (2019) Xing Qiu et al. ORGANIC LETTERS
- Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges
- (2019) Scott D. Edmondson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
- (2019) George M Burslem et al. CANCER RESEARCH
- Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
- (2019) Hao Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
- (2019) Jessica N. Spradlin et al. Nature Chemical Biology
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
- (2019) Xiaoyu Zhang et al. Nature Chemical Biology
- Plasticity of the Cullin-RING Ligase Repertoire Shapes Sensitivity to Ligand-Induced Protein Degradation
- (2019) Cristina Mayor-Ruiz et al. MOLECULAR CELL
- Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway
- (2019) Philipp Ottis et al. ACS Chemical Biology
- PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
- (2019) Xiuyun Sun et al. BIOCHEMISTRY
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Triazol: a privileged scaffold for proteolysis targeting chimeras
- (2019) Li-Wen Xia et al. Future Medicinal Chemistry
- Structure-Based Design of a Macrocyclic PROTAC
- (2019) Andrea Testa et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
- (2019) Saul Jaime-Figueroa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space
- (2018) Vasanthanathan Poongavanam et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
- (2018) Mengchen Lu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Delineating the role of cooperativity in the design of potent PROTACs for BTK
- (2018) Adelajda Zorba et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
- (2018) Kristin M. Riching et al. ACS Chemical Biology
- Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity
- (2018) Jinlei Bian et al. BIOORGANIC CHEMISTRY
- Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
- (2018) Joseph Schoepfer et al. JOURNAL OF MEDICINAL CHEMISTRY
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
- (2018) Vittoria Zoppi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
- (2018) Yangbing Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
- (2018) George M. Burslem et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- In VivoKnockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)
- (2017) Nobumichi Ohoka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection
- (2017) David A. DeGoey et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
- (2017) Andrew P. Crew et al. JOURNAL OF MEDICINAL CHEMISTRY
- A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation
- (2017) Ryan P. Wurz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
- (2017) Kwok-Ho Chan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- Deubiquitylating enzymes and drug discovery: emerging opportunities
- (2017) Jeanine A. Harrigan et al. NATURE REVIEWS DRUG DISCOVERY
- A General Strategy for the Preparation of Thalidomide-Conjugate Linkers
- (2017) Darren Derksen et al. SYNLETT
- Cell permeability beyond the rule of 5
- (2016) Pär Matsson et al. ADVANCED DRUG DELIVERY REVIEWS
- A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
- (2016) Mary E. Matyskiela et al. NATURE
- CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
- (2015) P. R. Hagner et al. BLOOD
- How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
- (2015) Bradley C. Doak et al. JOURNAL OF MEDICINAL CHEMISTRY
- Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
- (2014) Bradley Croy Doak et al. CHEMISTRY & BIOLOGY
- Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
- (2014) Carles Galdeano et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
- (2012) Christopher A. Lipinski et al. ADVANCED DRUG DELIVERY REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now